Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07034131

Evaluation of Osteo-Buddy in Improving Osteoporosis Knowledge

This is a pilot randomised controlled trial (RCT) to evaluate the use of a Virtual Health Assistant (VHA) named Osteo-Buddy in improving the knowledge of osteoporosis in older women.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Osteoporosis Risk Bone Diseases Bone Diseases, Metabolic Metabolic Diseases Musculoskeletal Diseases Nutritional and Metabolic Diseases Osteoporosis Osteoporosis, Postmenopausal

Age range

50 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

About this study

This study will involve evaluating the preliminary effectiveness and feasibility outcomes of the use of Osteo-Buddy, a Virtual Health Assistant (VHA), in improving the knowledge of osteoporosis in women aged 50 and above.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 50 and above
  • Medium or high Osteoporosis Self-Assessment Tool for Asians (OSTA) score
  • Not undertaken Bone Mineral Density (BMD) scan
  • Never been treated with anti-osteoporosis medications such as bisphosphonates (e.g. alendronate, risendronate, ibandronate, zolendronate, pamidronate) or denosumab
  • Able to read and speak English
  • Currently use and own a smartphone where Osteo-Buddy can be used

Exclusion criteria

  • Known terminal illness
  • Visual, hearing and/or cognitive impairment or mental illness that renders them unable to provide informed consent

Treatment and study plan

Osteo-Buddy

Other

Osteo-Buddy is a Virtual Health Assistant (VHA) accessible on mobile phones that helps users with:

  • Evaluating their risk level of osteoporosis
  • Recommending screening and referrals
  • Lifestyle interventions through motivation, education and tailored guidance

As a 24/7 VHA, it offers real-time, personalised advice based on user inputs and health data.

Usual Care

Other

Access to digitalised educational materials on osteoporosis, titled 'Healthy Bones'

Primary outcomes

  1. Osteoporosis Prevention and Awareness Tool (OPAAT) score

    Time frame: On enrolment and 6-8 weeks post enrolment

    • 30-item questionnaire measuring osteoporosis knowledge
    • Minimum value = 0, maximum value = 30
    • Higher scores indicate a better outcome

  2. System Usability Scale (SUS)

    Time frame: 6-8 weeks post enrolment

    • 10-item questionnaire assessing usability
    • Minimum value = 0, maximum value = 100
    • Higher scores mean a better outcome

Secondary outcomes

  1. Recruitment rate

    Time frame: over the course of recruitment, estimated 3-4 months

    Percentage of participants successfully recruited among referred participants

  2. Retention rate

    Time frame: 6-8 weeks post-enrolment

    Percentage of recruited participants who complete the study (return for 2nd visit and successfully complete 2nd questionnaire)

  3. Utility rate

    Time frame: 4 weeks

    Percentage of intervention arm participants who utilise Osteo-Buddy over the 4 weeks

Study contacts

Contact information is provided by the study sponsor or research team.

Eunice Lim

CONTACT

[email protected]

+65 6340 7436

Sponsors and collaborators

Lead sponsor

SingHealth Polyclinics

Other

Registry information

Official study title

Improving Both Health in Women With the Use of Osteo-Buddy to Enhance Osteoporosis Knowledge - A Mixed Method Clinical Trial

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jun 24, 2025
Registry last updated
Jul 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.